Zejula

What Zejula Means in Everyday Medical Language

Zejula is the brand name for a cancer medicine called niraparib tosylate monohydrate. It belongs to a group of drugs known as PARP inhibitors. These drugs work by blocking an enzyme that cancer cells need to repair damaged DNA. When cancer cells cannot fix their DNA, they may die or stop growing. Zejula is taken by mouth and is mainly used to treat certain cancers of the ovaries, fallopian tubes, or the lining of the abdomen (called primary peritoneal cancer).

Besides being used alone, niraparib tosylate monohydrate is also part of a combination medicine called Akeega. Akeega includes niraparib, abiraterone acetate, and prednisone, and is used to treat some adults with prostate cancer that has spread and no longer responds to hormone-lowering treatments.

Why Zejula Can Matter in Cancer Care

Cancers like ovarian and prostate cancer can be challenging to treat, especially when they return after initial therapy or stop responding to standard treatments. Zejula targets a specific weakness in cancer cells—their need to repair damaged DNA to survive. By blocking this repair process, Zejula may slow cancer growth or help keep cancer under control.

When combined with other drugs in Akeega, it offers a two-part approach for prostate cancer by both blocking DNA repair and lowering male hormone levels that some prostate cancers need to grow. This combination can be especially helpful for patients with certain genetic changes, such as mutations in the BRCA1 or BRCA2 genes, which affect DNA repair.

What Patients Might See or Hear About Zejula

Patients may hear the name Zejula as the brand name for niraparib tosylate monohydrate when used alone. When combined with abiraterone acetate and prednisone, the medicine is called Akeega. These names might appear in medical reports, treatment plans, prescriptions, or discussions with the cancer care team. Because the drug can appear under different names or as part of a combination, it can be confusing.

Understanding that these names refer to the same or related treatments can help patients ask informed questions about how the medicine works and what to expect during treatment. Side effects may include nausea, tiredness, low blood counts, and others, so discussing these with your care team is important.

Where the Term Might Appear

You might see niraparib tosylate monohydrate or Zejula mentioned in your medical records, treatment plans, or drug information sheets. It may also appear in clinical trial listings if you are exploring research studies. When used as part of Akeega, it will be noted alongside abiraterone acetate and prednisone, especially in the context of prostate cancer treatment.

Reading these terms carefully and asking your care team to explain how they relate to your treatment can help you understand your care better.

What the Term Does Not Automatically Mean

Seeing the term niraparib tosylate monohydrate, Zejula, or Akeega does not mean you will receive this treatment or that it will cure cancer. It is one option among many and is used for specific types of cancer and patient situations. For example, Akeega is mainly for prostate cancer that has spread and stopped responding to hormone-lowering treatments, often with certain genetic changes.

Each patient’s treatment plan is unique, so these terms are part of a larger conversation about what is best for you.

Safety and Next Steps

This information is meant to help you understand what Zejula is and how it may be used in cancer care. It is not a substitute for medical advice. If you see these terms in your medical records or hear them from your care team, the best next step is to ask your doctor or nurse what they mean for your specific situation. They can explain how this medicine fits into your treatment plan, what benefits and risks it may have, and what to expect during therapy.